PMID- 11509117
OWN - NLM
STAT- MEDLINE
DCOM- 20011205
LR  - 20240324
IS  - 0910-5050 (Print)
IS  - 1876-4673 (Electronic)
IS  - 0910-5050 (Linking)
VI  - 92
IP  - 8
DP  - 2001 Aug
TI  - Frequent increase of DNA copy number in the 2q24 chromosomal region and its 
      association with a poor clinical outcome in hepatoblastoma: cytogenetic and 
      comparative genomic hybridization analysis.
PG  - 854-62
AB  - In a cytogenetic and comparative genomic hybridization (CGH) study of 38 
      hepatoblastomas, we found gain of 1q in 17 tumors (44.7%), that of 2 / 2q in 14 
      (36.8%), that of 20 / 20q in 9 (23.7%) and that of 8 / 8q in 8 (21.0%), loss of 
      4q in 4 (10.5%) and no DNA copy changes with normal karyotype or no mitotic cells 
      in 11 (28.9%). Eleven tumors with 2 / 2q gain detected by CGH had a total 
      chromosome 2 gain, a partial 2q gain, or a total chromosome 2 gain with an 
      augmented partial 2q region; the common region for DNA copy gain was 2q24. 
      Two-color fluorescence in situ hybridization (FISH) analyses using probes 
      covering the centromere of chromosome 2 or HOXD13 (2q31) confirmed the CGH 
      findings, and showed that the common region for gain in 2q was centromeric to 
      HOXD13. Event-free survival (EFS) +/- standard error (SE) at 5 years was lowest 
      in patients with 2q gain [37 +/- 15%], highest in those with no DNA copy changes 
      [82 +/- 12%], and intermediate in those with DNA copy changes other than 2q gain 
      [74 +/- 13%] (P = 0.0549). Multivariate analysis showed that 2q gain was an 
      independent factor predicting a poor outcome. These findings suggest the presence 
      of a growth-promoting gene or an oncogene in the 2q24 chromosome band, and a 
      tumor suppressor gene in terminal 4q, which have important roles in the 
      development and progression of hepatoblastoma.
FAU - Kumon, K
AU  - Kumon K
AD  - Department of Cancer Chemotherapy, Saitama Cancer Center Hospital, Ina, Saitama 
      362-0806, Japan.
FAU - Kobayashi, H
AU  - Kobayashi H
FAU - Namiki, T
AU  - Namiki T
FAU - Tsunematsu, Y
AU  - Tsunematsu Y
FAU - Miyauchi, J
AU  - Miyauchi J
FAU - Kikuta, A
AU  - Kikuta A
FAU - Horikoshi, Y
AU  - Horikoshi Y
FAU - Komada, Y
AU  - Komada Y
FAU - Hatae, Y
AU  - Hatae Y
FAU - Eguchi, H
AU  - Eguchi H
FAU - Kaneko, Y
AU  - Kaneko Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Jpn J Cancer Res
JT  - Japanese journal of cancer research : Gann
JID - 8509412
RN  - 0 (Antineoplastic Agents)
RN  - 0 (DNA, Neoplasm)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Child, Preschool
MH  - Chromosome Aberrations
MH  - Chromosomes, Human, Pair 1/genetics
MH  - Chromosomes, Human, Pair 2/*genetics
MH  - DNA, Neoplasm/*genetics
MH  - Female
MH  - *Gene Dosage
MH  - Genome
MH  - Hepatoblastoma/*genetics/mortality
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Infant
MH  - Infant, Newborn
MH  - Japan/epidemiology
MH  - Karyotyping
MH  - Liver Neoplasms/*genetics/mortality
MH  - Male
MH  - Nucleic Acid Hybridization
MH  - Survival Rate
PMC - PMC5926834
EDAT- 2001/08/18 10:00
MHDA- 2002/01/05 10:01
PMCR- 2001/08/01
CRDT- 2001/08/18 10:00
PHST- 2001/08/18 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/08/18 10:00 [entrez]
PHST- 2001/08/01 00:00 [pmc-release]
AID - CAE854 [pii]
AID - 10.1111/j.1349-7006.2001.tb01172.x [doi]
PST - ppublish
SO  - Jpn J Cancer Res. 2001 Aug;92(8):854-62. doi: 10.1111/j.1349-7006.2001.tb01172.x.